Pancreatic Cancer Research

ResearcherNational Cancer Centre JapanActive in the last 2 years

Minoru Esaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9631-6178; OpenAlex author ID A5087487207. Sources: OpenAlex.

Their work

Papers
18 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
45
Papers, trials and grants by year

2012: 3 papers · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 3 papers · 2023: none · 2024: 3 papers · 2025: 2 papers · 2026: 4 papers

Papers 18

  1. MIF-CD74 axis facilitates MDSC infiltration in the tumor microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218348↗
  2. Corrigendum to "MIF-CD74 axis facilitates MDSC infiltration in the tumor microenvironment of pancreatic ductal adenocarcinoma" [Cancer Lett. 645, (2026), 21834… Co-author DOI 10.1016/j.canlet.2026.218794↗
  3. Percutaneous abdominal lavage cytology screening reduces non-therapeutic laparotomy in patients with pancreatic cancer considered for curative-intent resection… Last author DOI 10.1016/j.surg.2026.110444↗
  4. Compact serum miRNA qPCR model for pancreatic cancer discrimination with independent and clinical validation Co-author DOI 10.64898/2026.05.11.724428↗
  5. Deep learning-based automatic detection of pancreatic ductal adenocarcinoma ≤ 2 cm with high-resolution computed tomography: impact of the combination of tumor… Co-author DOI 10.1007/s11604-025-01836-z↗
  6. Neoadjuvant gemcitabine and S-1 in pancreatic ductal adenocarcinoma: Effects on nutritional status and pancreaticoduodenectomy outcomes. Last author DOI 10.1016/j.surg.2024.109026↗
  7. Oligo-like liver metastasis: A novel prognostic indicator to improve survival in pancreatic cancer. Co-author DOI 10.1002/ags3.12753↗
  8. Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy. Co-author DOI 10.1002/cam4.70474↗
  9. Safety and feasibility of percutaneous abdominal lavage cytology screening (PACS) prior to surgical resection for pancreatic cancer. Last author DOI 10.1007/s00261-024-04510-6↗
  10. Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5. Co-author DOI 10.1038/s41416-021-01639-9↗
  11. Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail. First author DOI 10.1245/s10434-022-11950-1↗
  12. ASO Author Reflections: Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail. First author DOI 10.1245/s10434-022-11957-8↗
  13. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients. Co-author DOI 10.1111/cas.14514↗
  14. Feasibility of resecting the portal vein only when necessary during pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1002/bjs5.50130↗
  15. Macroscopic features predict outcome in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00428-016-2026-6↗
  16. Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy. Co-author DOI 10.1016/j.pan.2012.07.016↗
  17. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Co-author DOI 10.1245/s10434-011-2020-9↗
  18. Total pancreatectomy with en bloc celiac axis resection for a pancreatic adenocarcinoma involving both the gastroduodenal artery and the celiac artery. Co-author DOI 10.5754/hge11687↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Satoshi Nara · 16 shared papers, 2012–2026 · strength 2.43
  2. Nobuyoshi Hiraoka · 10 shared papers, 2016–2026 · strength 1.62
  3. Daisuke Ban · 6 shared papers, 2022–2026 · strength 1.32
  4. Kazuaki Shimada · 10 shared papers, 2012–2024 · strength 1.05
  5. Takeshi Takamoto · 5 shared papers, 2022–2025 · strength 1.02
  6. Shunsuke Sugawara · 4 shared papers, 2022–2026 · strength 0.78
  7. Ryosuke Umino · 2 shared papers, 2024–2026 · strength 0.48
  8. Yoji Kishi · 5 shared papers, 2012–2022 · strength 0.45
  9. Mizuki Ozawa · 2 shared papers, 2024–2025 · strength 0.41
  10. Keisuke Sekine · 2 shared papers, 2026 · strength 0.40
  11. Kazunori Aoki · 2 shared papers, 2026 · strength 0.40
  12. Hiroyuki Tsunoda · 2 shared papers, 2026 · strength 0.40
  13. Hironori Fukuda · 2 shared papers, 2026 · strength 0.40
  14. Atsushi Ochiai · 2 shared papers, 2026 · strength 0.40
  15. Kei Kitamura · 2 shared papers, 2022 · strength 0.30
  16. Yoshinori Ino · 3 shared papers, 2016–2022 · strength 0.29
  17. Sunao Yotsutsuji · 1 shared paper, 2026 · strength 0.29
  18. Yoshitake Sano · 1 shared paper, 2026 · strength 0.29
  19. Ryo Saito · 1 shared paper, 2024 · strength 0.24
  20. Susumu Hijioka · 1 shared paper, 2025 · strength 0.23
  21. Yoshiyuki Matsui · 1 shared paper, 2025 · strength 0.23
  22. Takuji Okusaka · 2 shared papers, 2012–2024 · strength 0.23
  23. Chigusa Morizane · 2 shared papers, 2012–2024 · strength 0.23
  24. Mariko Nishioka · 1 shared paper, 2024 · strength 0.20
  25. Tomoyuki Satake · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.